David Craig publishes biotech founder guide amid tougher funding market

David R. Craig, founder and CEO of Sarcomatrix Therapeutics, has released a new book aimed at helping biotech founders, investors and operators adapt to tighter capital markets and evolving regulatory demands. The book argues that today’s biotech companies need capital discipline, milestone-based execution and strong science to succeed. Why it matters: - Biotech startups are operating in a less forgiving market than the 2020-2021 funding boom. - The book targets founders, investors and operators who need practical guidance on financing, regulation and execution. - Craig frames capital efficiency and operational discipline as now central to building biotech companies. What happened: - David R. Craig, MBA, announced the publication of The New Rules of Biotech: A Founder’s Guide to Building Great Companies . - Craig is founder and CEO of Sarcomatrix Therapeutics and a biotechnology industry veteran with nearly 40 years of experience. - The book is available now in paperback and Kindle. - The publication date is June 6, 2026. The details: - The book covers financing strategy, milestone-based fundraising, non-dilutive capital, regulatory planning, asset development, manufacturing, strategic partnerships and exit planning. - It also examines shifting venture financing dynamics, capital efficiency and disciplined execution across drug development. - Craig has worked in life sciences since 1986 and has founded and advised multiple biotechnology ventures. - His background spans drug development, capital formation, regulatory strategy and commercialization. - The paperback price is $24.99. - The Kindle price is $14.99. - The book is published by D. Craig Consulting LLC. - It is available through Amazon now: Purchase on Amazon . - The Kindle edition is listed here: Kindle edition . - Additional distribution through Apple Books, Kobo, Google Play and IngramSpark is forthcoming. - The ISBN is 979-8-9965766-0-9. - The book is categorized under Business & Money and Business Development & Entrepreneurship. Between the lines: - Craig is positioning the book as a response to a structural reset in biotech financing and development timelines. - The message reflects a broader industry shift away from growth-at-all-costs toward milestone discipline and clearer paths to value creation. - Craig ties the book to his own operating experience at Sarcomatrix Therapeutics, where the company is advancing S-969 toward first-in-human studies. - Sarcomatrix was founded in part through Craig’s personal connection to rare genetic muscle diseases, reinforcing the book’s patient-focused framing. What’s next: - Sarcomatrix Therapeutics plans to continue advancing S-969, its lead therapeutic candidate for muscle-wasting diseases, toward first-in-human studies. - The book is expected to expand to Apple Books, Kobo, Google Play and IngramSpark. - Craig will likely use the book and his operating background to continue speaking to biotech founders and investors navigating today’s market. The bottom line: - Craig’s book argues that biotech success now requires more than promising science. It demands disciplined capital use, regulatory foresight and execution that can survive a tougher funding environment.